Evidence map›Paper›PMID 38009329›Full record

ArticleStatistics in medicine2024

Designing individually randomized group treatment trials with repeated outcome measurements using generalized estimating equations.

Xueqi Wang, Elizabeth L Turner, Fan Li

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Statistics in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06798662 (Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06798662 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain: a Prospective, Randomized, Controlled, Triple-blind Trial

TypeinterventionalSponsorXiaguang DuanRan2025 to 2025Enrolled120ConditionsHerpes Zoster (HZ)ArmsUltrasound-Guided Pulsed Radiofrequency (PRF), Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine), Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine), Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine), Drug (famciclovir and gabapentin)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xueqi WangDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-9449-5451
Elizabeth L TurnerDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-7638-5942
Fan LiDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0001-6183-1893
Duke University · USYale University · US

Funding

NIH Health Care Systems Research Collaboratory-Coordinating Center (U24)U24AT009676 · NCCIH · DUKE UNIVERSITY · PI LESLEY H CURTIS, Adrian Hernandez · 2017 to 2026
$21.5M
HEAL Collaboratory Resource Coordinating Center (PRISM) (U24): Bioethics SupplementU24AT010961 · NCCIH · DUKE UNIVERSITY · PI CURTIS, LESLEY H, HERNANDEZ, ADRIAN · 2019 to 2021
$6.4M
North STAR Trial: Specialty Telemedicine Access for Referrals in Rural AlaskaR01DC020026 · NIDCD · UNIV OF ARKANSAS FOR MED SCIS · PI EMMETT, SUSAN DAVIS, HIRSCHFELD, MATTHEW J · 2021 to 2025
$3.3M
SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian YouthR01MH124476 · NIMH · DUKE UNIVERSITY · PI DOW, DOROTHY E. · 2021 to 2025
$2.5M
Appalachian STAR TrialU01OD033247 · OD · UNIV OF ARKANSAS FOR MED SCIS · PI BUSH, MATTHEW LEE, EMMETT, SUSAN DAVIS · 2021 to 2021
$1.8M
NCCIH NIH HHS U24 AT009676NCCIH NIH HHS U24 AT010961NIDCD NIH HHS R01 DC020026NIH HHS R01DC020026NIH HHS R01-MH124476NIH HHS U01 OD033247NIH HHS U01OD033247NIH HHS U24AT009676NIH HHS U24AT010961NIMH NIH HHS R01 MH124476
6 · The paper itself

Abstract

Individually randomized group treatment (IRGT) trials, in which the clustering of outcome is induced by group-based treatment delivery, are increasingly popular in public health research. IRGT trials frequently incorporate longitudinal measurements, of which the proper sample size calculations should account for correlation structures reflecting both the treatment-induced clustering and repeated outcome measurements. Given the relatively sparse literature on designing longitudinal IRGT trials, we propose sample size procedures for continuous and binary outcomes based on the generalized estimating equations approach, employing the block exchangeable correlation structures with different correlation parameters for the treatment arm and for the control arm, and surveying five marginal mean models with different assumptions of time effect: no-time constant treatment effect, linear-time constant treatment effect, categorical-time constant treatment effect, linear time by treatment interaction, and categorical time by treatment interaction. Closed-form sample size formulas are derived for continuous outcomes, which depends on the eigenvalues of the correlation matrices; detailed numerical sample size procedures are proposed for binary outcomes. Through simulations, we demonstrate that the empirical power agrees well with the predicted power, for as few as eight groups formed in the treatment arm, when data are analyzed using the matrix-adjusted estimating equations for the correlation parameters with a bias-corrected sandwich variance estimator.

Indexed as

Models, StatisticalResearch DesignBiasCluster AnalysisComputer SimulationHumansSample Sizeindividually randomized group treatment trialsmatrix-adjusted estimating equationspowersample size calculationsandwich variance estimator

Identifiers

PMID38009329
PMCPMC10939061
OpenAlexW4389037906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.